Quick summary: SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination .
SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination
Recommended action: compare your product with the official notice and follow the instructions published by the official source.
Recall details
Quick summary: SOLIRIS (eculizumab) - Increased Risk of Hemolysis or Low Hemoglobin with Serogroup B Meningococcal Vaccination .
Affected product details
Structured information extracted from the official recall notice. Confirm the identifiers and instructions in the original notice.
Affected products
Issue
During a safety review of Bexsero, a vaccine used to protect against Neisseria meningitides serogroup B, Health Canada found more reports of serious adverse reactions with Bexsero in patients with complement mediated diseases (such as paroxysmal nocturnal hemoglobinuria [PNH] and atypical haemolytic uremic syndrome [atypical HUS]) who were being treated with SOLIRIS (a complement inhibitor), than in other patients vaccinated with Bexsero. Bexsero was marketed in Canada in 2014, which is 5 years after SOLIRIS (marketed since 2009). A further review of the reports with Bexsero in patients already being treated with SOLIRIS concluded that there was an increased risk of low hemoglobin, including anemia, or hemolysis. The risk was highest in patients receiving Bexsero vaccine when their predicted systemic SOLIRIS concentrations were relatively low.
What you should do
Additional official information
Contains information licensed under the Open Government Licence – Canada. SafetyPulse is independent of the Government of Canada.
Frequently asked questions
Answers based on the official recall notice.
Product images
Official product images from Health Canada.
Starting...
Explore more
Related recalls
Similar recalls and safety notices.